表紙
市場調查報告書

基因測試市場:全球市場的預測/分析 (應用/技術),新冠病毒傳染病(Covid-19)的影響,執行及諮詢指南(2020∼2024年)

Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2020 to 2024

出版商 Howe Sound Research 商品編碼 940592
出版日期 內容資訊 英文 429 Pages
商品交期: 最快1-2個工作天內
價格
基因測試市場:全球市場的預測/分析 (應用/技術),新冠病毒傳染病(Covid-19)的影響,執行及諮詢指南(2020∼2024年) Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2020 to 2024
出版日期: 2020年06月05日內容資訊: 英文 429 Pages
簡介

此報告針對基因檢測未來的技術進步/市場成長前景進行分析,統整技術概要以及主要活用領域,對未來醫療現場的影響力,目前的主要開發/產品上市的動向,主要企業的簡介及主力產品,未來的市場規模趨勢前景,各地區/各應用/各技術的詳細趨勢,新冠病毒傳染病(Covid-19)的影響等資訊。

目次

i. 基因測試市場:策略狀況分析及Covid-19的影響

ii. 適合營運/行銷/銷售/商業開發工作人員的指南

iii. 經營諮詢/投資顧問指南

第1章 簡介,市場定義

第2章 市場概況

  • 市場參與者扮演不同角色
    • 供應商/製藥企業
    • 獨立實驗室:專業/罕見疾病
    • 獨立實驗室:各國/各地區
    • 獨立實驗室:分析
    • 國營/公營實驗室
    • 醫院檢查室
    • 執業醫師檢查室
    • DTC檢查室
    • 獨立基因檢查室
    • 監管機關
  • 基因測試-種類,範例,考察
    • 胚胎著床前基因診斷-新興市場
    • 出生前診斷-新科技衍生出機會
    • 新生兒檢查
    • 診斷測試
    • 營運商測試
    • 預測測試/症狀前測試
    • 藥物基因組學
    • 法醫學測試
    • 家長測試
    • 祖先測試
  • 產業結構
    • 醫院檢測市佔率
    • 規模經濟
    • 內科醫院
    • 醫師與POCT
  • 主要基因學參與者的市佔率分析

第3章 市場趨勢

  • 推動市場成長因素
  • 控制市場成長因素
  • 儀表及自動化
  • 診斷技術的開發
    • 次世代定序 (NGS):推動革命
    • 對NGS價格設定的影響
    • POCT:自我測試具顛覆性
    • 藥物基因組學:診斷及治療的一體化
    • CGES測試:開拓新世界
    • 生物晶片/巨磁阻測定

第4章 基因測試:近年進展

  • 此領域的重要性及活用方法

第5章 主要企業簡介

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

第6章 全球市場規模

  • 各國分析:概述
  • 各應用分析:概述
  • 不同技術分析:概述

第7章 不同應用之市場規模

  • 新生兒檢測
  • NIPT (非侵入性產前檢測)
  • 預測檢測
  • 腫瘤檢測
  • DTC (消費者基因檢測)
  • 其他

第8章 基因測試市場:不同技術

  • PCR (聚合□鏈鎖反應) 檢測
  • NGS (次世代定序)
  • 細胞遺傳學測試
  • 其他

第9章 基因測試的未來

附錄

目錄

OVERVIEW:

Large genetic testing cancer segment impacted by COVID-19. Genetic Blizzard creating confusing array of new tests.

Will all newborns receive Whole Genomic Sequencing at birth? What has happened to Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Genetic Testing Definition in This Report
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
    • 1.3.1. Newborn Screening
    • 1.3.2. Non Invasise Pregnancy Testing
    • 1.3.3. Predictive
    • 1.3.4. Oncology
    • 1.3.5. Direct to Consumer
    • 1.3.6. Other Application
    • 1.3.7. PCR
    • 1.3.4. NGS
    • 1.3.5. Cytogenetic
    • 1.3.6. Other Technology
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Supplier/pharmaceutical
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Independent Genetic Testing Lab
    • 2.1.10. Audit Body
  • 2.2. Genetic Tests -Types, Examples and Discussion
    • 2.2.1. Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2. Prenatal Diagnosis-New Technologies Create Opportunity
    • 2.2.3. Newborn Screening
    • 2.2.2. Diagnostic Testing
    • 2.2.3. Carrier Testing
    • 2.2.6. Predictive and Presymptomatic Testing
    • 2.2.7. Pharmacogenomics
    • 2.2.8. Forensic Testing
    • 2.2.9. Parental Testing
    • 2.2.10. Ancestral Testing
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
      • 2.3.2.1. Hospital vs. Central Lab
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2. Aging Population a Boon for Diagnostics
    • 3.1.3. Pharmacogenomics Drives Further Growth.
    • 3.1.4. Oncology and Liquid Biopsy Enter New Era
    • 3.1.5. Fertility Practice Growth drives market
    • 3.1.6. Direct to Consumer begins to break out
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Testing usage analysis curtailing growth.
    • 3.2.4. Wellness has a downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution.
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. POCT/Self Testing Disruptive Force
    • 3.4.4. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5. CGES Testing, A Brave New World
    • 3.4.6. Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1. Importance of This Section
  • 4.1.2. How to Use This Section
    • Preconception Carrier Screening Trial Begins in Australia
    • Genetic Testing Clinical Use Just Beginning
    • Fulgent Genetics Q1 Revenues Jump 44 Percent
    • Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic,
    • Hematologic Disorders
    • Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests
    • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
    • Thermo Fisher Scientific to Buy Qiagen for $11.5B
    • PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England
    • Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study
    • Qiagen, NeuMoDx Ink Partnership, Merger Agreement

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1. Global Market by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart-Key Country Densities
  • 6.2. Global Market by Application
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Application Share by Year
    • 6.2.3. Chart-Application Segment Growth Rates
    • 6.2.4. Chart-Application Segment Share Shifts
    • 6.2.5. Chart-Application Segment Share Base Year
    • 6.2.6. Chart-Application Segment Share Final Year
  • 6.3. Global Market by Technology
    • 6.3.1. Table-Global Market by Technology
    • 6.3.2. Chart-Technology Share by Year
    • 6.3.3. Chart-Technology Segment Growth Rates
    • 6.3.4. Chart-Technology Segment Share Shifts
    • 6.3.5. Chart-Technology Segment Share Base Year
    • 6.3.6. Chart-Technology Segment Share Final Year

7. Market Sizes by Application

  • 7.1. Newborn Testing Market
    • 7.1.1. Table Newborn-by Country
    • 7.1.2. Chart-Newborn Growth
  • 7.2. NIPT Market
    • 7.2.1. Table NIPT-by Country
    • 7.2.2. Chart-NIPT Growth
  • 7.3. Predictive Testing Market
    • 7.3.1. Table Predictive-by Country
    • 7.3.2. Chart-Predictive Growth
  • 7.4. Oncology Testing Market
    • 7.4.1. Table Oncology-by Country
    • 7.4.2. Chart-Oncology Growth
  • 7.5. DTC Testing Market
    • 7.5.1. Table DTC-by Country
    • 7.5.2. Chart-DTC Growth
  • 7.6. Other Testing Market
    • 7.6.1. Table Other-by Country
    • 7.6.2. Chart-Other Growth

8. Global Genetic Testing Market by Technology

  • 8.1. PCR Testing Market
    • 8.1.1. Table PCR-by Country
    • 8.1.2. Chart-PCR Growth
  • 8.2. NGS Market
    • 8.2.1. Table NGS-by Country
    • 8.2.2. Chart-NGS Growth
  • 8.3. Cytogenetic Testing Market
    • 8.3.1. Table Cytogenetic-by Country
    • 8.3.2. Cytogenetic-Predictive Growth
  • 8.4. Other Testing Market
    • 8.4.1. Table Other-by Country
    • 8.4.2. Chart-Other Growth

9. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II Methodology
    • II.1 Authors
    • II.2 Sources

Table of Tables

  • Table 1: Most Common Traditional Genetic Disorders
  • Table 2: Lab Spending 2014 to 2024
  • Table 3: Market Players by Type
  • Table 4: The Different Types of Genetic Tests
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Global Market by Country
  • Table 10: Global Market by Application
  • Table 11: Global Market by Technology
  • Table 12: Newborn Segment by Country
  • Table 13: NIPT Segment by Country
  • Table 14: Predictive Segment by Country
  • Table 15: Oncology Segment by Country
  • Table 16: DTC Segment by Country
  • Table 17: Other Segment by Country
  • Table 18: PCR Segment by Country
  • Table 19: NGS Segment by Country
  • Table 20: Cytogenetic Segment by Country
  • Table 21: Other Segment by Country
  • Table 22: 2020 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Top Ten Sequencing Companies
  • Figure 3: Percentage of World Population Over 65
  • Figure 4: Key Countries
  • Figure 5: Application Share by Year
  • Figure 6: Application Segment Growth Rates
  • Figure 7: Segment Share Shifts
  • Figure 8: Application Segment Share Base Year
  • Figure 9: Application Segment Share Final Year
  • Figure 10: Technology Share by Year
  • Figure 11: Technology Segment Growth Rates
  • Figure 12: Technology Segment Share Shifts
  • Figure 13: Technology Segment Share Base Year
  • Figure 14: Technology Segment Share Final Year
  • Figure 15: Newborn vs. Total Market Growth
  • Figure 16: NIPT vs. Total Market Growth
  • Figure 17: Predictive vs. Total Market Growth
  • Figure 18: Oncology vs. Total Market Growth
  • Figure 19: DTC vs. Total Market Growth
  • Figure 20: Other vs. Total Market Growth
  • Figure 21: PCR vs. Total Market Growth
  • Figure 22: NGS vs. Total Market Growth
  • Figure 23: Cytogenetic vs. Total Market Growth
  • Figure 24: Other vs. Total Market Growth